Supplemental material
Modern Rheumatology
Volume 27, 2017 - Issue 2
Open access
4,499
Views
48
CrossRef citations to date
0
Altmetric
Original Article
Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab
Yoshiya TanakaFirst Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, Correspondence[email protected]
, Hisashi YamanakaInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan,
, Tsutomu TakeuchiDivision of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan,
, Makoto InoueInoue Hospital, Gunma, Japan,
, Kazuyoshi SaitoFirst Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan,
, Yukihiko SaekiNHO Osaka Minami Medical Center, Osaka, Japan,
, Sang Joon LeeData Center, Product Development, Celltrion, Inc., Incheon, Republic of Korea,
& Yoshihiro NambuPharmaceuticals Group, Nippon Kayaku Co., Ltd., Tokyo, Japan
show all
Pages 237-245
|
Received 16 Mar 2016, Accepted 06 Jun 2016, Published online: 01 Sep 2016
Related Research Data
Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis
Source:
Taylor & Francis
Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.
Source:
Wiley
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis
Source:
Wiley
The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis
Source:
Informa UK Limited
MODIFIED DISEASE ACTIVITY SCORE
Source:
Wiley
Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
Source:
Springer Nature
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
Source:
Springer Science and Business Media LLC
Nocebos in rheumatology: emerging concepts and their implications for clinical practice
Source:
Springer Science and Business Media LLC
Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology
Source:
Springer Science and Business Media LLC
Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases
Source:
Informa UK Limited
Maintained Clinical Remission in Ankylosing Spondylitis Patients Switched from Reference Infliximab to Its Biosimilar: An 18-Month Comparative Open-Label Study
Source:
Multidisciplinary Digital Publishing Institute
Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases
Source:
Informa UK Limited
Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases
Source:
Informa UK Limited
Switching to biosimilars: current perspectives in immune-mediated inflammatory diseases
Source:
Informa UK Limited
Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.
Source:
Springer Science and Business Media LLC
Measurement of patient outcome in arthritis.
Source:
Wiley
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.